BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AstraZeneca (AZN) Commences Patent Infringement Litigation Against IVAX Corporation (IVX)


3/8/2006 2:32:43 PM

WILMINGTON, Del., March 8 /PRNewswire-FirstCall/ -- AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against IVAX Corporation, IVAX Pharmaceuticals, Inc. and Zenith Laboratories, Inc. (collectively "IVAX"), and IVAX's parent, Teva Pharmaceutical Industries Ltd. and its US subsidiary, Teva Pharmaceuticals USA, for willful infringement of AstraZeneca's patents protecting NEXIUM(R) (esomeprazole magnesium).

The lawsuit is in response to an Abbreviated New Drug Application filed by IVAX with the U.S. Food and Drug Administration regarding IVAX's intent to market a generic version of AstraZeneca's NEXIUM in the US prior to the expiration of five AstraZeneca Patents: 5,714,504; 5,877,192; 6,369,085; 6,428,810; and 6,875,872. The expiration dates for these patents range from 2014 through to 2019.

AstraZeneca has full confidence in and will continue vigorously to defend and enforce its intellectual property rights protecting NEXIUM.

AstraZeneca

CONTACT: Media Inquiries, Cynthia Callaghan, +1-302-886-2959, or DavidAlbaugh, +1-302-886-7098, or Investor Relations, Ed Seage, +1-302-886-4065,or Jorgen Winroth, +1-212-579-0506, all for AstraZeneca



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES